About
Founder-Led, Platform-Driven
VestraNova Therapeutics was founded by Ryan Nail to pursue a scaffold-first approach to antibody engineering.
Who We Are
Built on a Structural Insight
The company is built on the view that immune-related development risk can be addressed earlier — at the structural framework level — rather than only after target-specific optimization.
Ryan leads platform strategy, intellectual property architecture, and company development.
Better therapeutic architecture may improve not only how biologics are developed, but how they may ultimately be used in patient care.
Principles
How We Work
Disciplined Technical Positioning
Design decisions are grounded in computational analysis and structural biology, not intuition or convention.
Careful Factual Representation
We maintain a clear boundary between public strategic science and confidential implementation detail. Claims are evidence-based and appropriately hedged.
Stepwise Validation Strategy
A structured approach aligned with long-term platform value — clear milestones, disciplined IP filings, and foundational validation before program expansion.
Leadership
Company Leadership
Ryan Nail
Founder & CEO
Ryan Nail founded VestraNova Therapeutics to pursue a scaffold-first approach to antibody engineering. He leads the company's platform strategy, intellectual property architecture, and strategic development.
Learn More About VestraNova
Detailed information about the company, platform, and development status is available under NDA for qualified parties.